Ulcerative Colitis

Even though COVID-19 infection disproportionately impacts minority patients, there’s no indication that vaccine intention differs depending on race in IBD patients.

This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.

In his lecture, The End of the Beginning: Megatrends in Gastroenterology, William Chey, MD, emphasizes the importance of a multidisciplinary integrated care approach to treating IBS.

An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

Patients in the open-label extension of the OASIS study saw increases in Inflammatory Bowel Disease Questionnaire (IBDQ) scores.

Investigators found fistulizing Crohn’s disease increases the healthcare burden and lengthens the duration of hospital stays in patients with acute kidney injuries.

Biologic therapies show promising results of clinical remission in patients with Crohn's disease.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

Patients with Crohn's disease often also suffer from kidney dysfunction.

Patients in both the ADVANCE and MOTIVATE studies achieved enhanced clinical response and endoscopic response.

Hypertension rates were low in both ulcerative colitis and multiple sclerosis patients treated with ozanimod, regardless of concurrent SNRI/SSRI use.

Gastrointestinal symptoms were significantly linked to severe symptoms of depression and anxiety.

Serious infections occurred in less than 2% of patients treated with the medication during the duration of the 52-week trial.

Taste scores were significantly correlated with depression scores for both patients with irritable bowel syndrome and functional constipation.

The ongoing PIANO registry is designed to keep real time data on the outcomes of pregnant patients with IBD.

The FODMAP diet is considered a preferable option for patients with irritable bowel syndrome.

Dr. Amar Deshpande said more safety studies are needed before examining whether multiple biologics can be used to treat IBD.

More research is needed on the safety and efficacy of multiple biologics.

IBS is considered 1 of the most expensive conditions in gastroenterology.

The US Food and Drug Association are also requiring new and updated warnings for baricitinib and upadacitinib, 2 other arthritis medicines in the same drug class as tofacitinib.

The study also showed cost savings for both standard and dose-intensified infliximab.

Both patients and physicians request more time for routine ulcerative colitis appointments.

Both Crohn’s disease and ulcerative colitis patients had a higher risk of IBD-related readmission and length of stay.

Both vedolizumab and ustekinumab are common treatments for inflammatory bowel disease.

The new diet program was compared to the existing front-line therapy of exclusive enteral nutrition.